HER2-low in gastro-oesophageal adenocarcinoma: a real-world pathological perspective

Conclusions
This work shows how the expansion of the HER2 spectrum might raise problems in reproducibility, especially in biopsy specimens, decreasing interlaboratory and interobserver concordance. If controlled trials confirm the promising activity of novel anti-HER2 agents in HER2-low gastro-oesophageal cancers, a shift in the interpretation of HER2 status may need to be pursued.

Source: Journal of Clinical Pathology - November 17, 2023 Category: Pathology Authors: Angerilli, V., Parente, P., Campora, M., Ugolini, C., Battista, S., Cassoni, P., Gambella, A., Cavallin, F., De Lisi, G., Vanoli, A., Grillo, F., Mastracci, L., Fassan, M. Tags: Original research Source Type: research